Company Report

McKesson has Total revenues of $62.6 billion, reflecting 6% growth in third-quarter 2020

McKesson Corporation (NYSE:MCK) reported results for the third quarter ended December 31, 2020.

Third-quarter revenues were $62.6 billion, up 6% from a year ago, driven by growth in the U.S. Pharmaceutical segment, largely due to market growth and higher specialty volumes, partially offset by branded to generic conversions.

Third-quarter revenues were $49.5 billion, up 7%, driven by market growth and higher specialty volumes, partially offset by branded to generic conversions.

Third-quarter revenues were $9.3 billion, down 6% on a reported basis and down 10% on an FXAdjusted basis, driven by the contribution of McKesson’s German wholesale business to a joint venture with Walgreens Boots Alliance.

Third-quarter revenues were $3.1 billion, up 43%, primarily driven by demand for COVID-19 tests in the Primary Care and Extended Care businesses.

Third-quarter revenues were $777 million, up 9%, driven by new brand support programs and higher volumes of existing brand support programs.

Source: investor.mckesson.com

Download PDF File from here.

Post Comment